Skip to main content

 

Skip to content
  • HOME
  • ABOUT
    VBL
    • COMPANY OVERVIEW
    • MANAGEMENT TEAM
    • BOARD OF DIRECTORS
    • ADVISORY BOARDS
  • CANCER
    PROGRAMS
    • CANCER PLATFORM & TECHNOLOGY
    • PUBLICATIONS
  • INFLAMMATION
    PROGRAMS
    • INFLAMMATORY PLATFORM
    • INFLAMMATORY PIPELINE
    • PUBLICATIONS
  • VB-600
    PLATFORM
    • OVERVIEW
    • TARGETING MOSPD2 FOR INFLAMMATION
    • TARGETING MOSPD2 FOR CANCER
    • PUBLICATIONS
  • PATIENTS &
    CAREGIVERS
    • CLINICAL TRIALS
    • COMPASSIONATE USE
  • INVESTOR
    RELATIONS
    • IR HOMEPAGE
    • PRESS RELEASES
    • EVENTS AND PRESENTATIONS
    • STOCK INFORMATION
    • ANALYST COVERAGE
    • CORPORATE GOVERNANCE
    • SEC FILINGS
    • INVESTOR FAQ & CONTACTS
  • PRESS RELEASES
  • PRESS RELEASE ARCHIVE

PRESS RELEASES

2021

2021

  • March 4, 2021 -
  • March 1, 2021 - VBL Therapeutics Announces Patient Dosing Initiated in Randomized, Controlled and Blinded Trial of VB-111 in Patients with Recurrent Glioblastoma Multiforme
  • February 22, 2021 - VBL Therapeutics Announces Data Safety Monitoring Committee Provides Green Light to Advance the OVAL Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer
  • January 27, 2021 - VBL Therapeutics Treats First Patient in Phase 2 Randomized Controlled Study of VB-201 in COVID-19 Patients
  • January 15, 2021 - VBL Therapeutics Enters Into Ordinary Share Purchase Agreement of up to $20 Million With Aspire Capital Fund, LLC
Follow Us on TwitterFollow Us on LinkedInFollow Us on FacebookFollow Us on YouTube

YOU ARE NOW LEAVING VBLRX.COM.

The site you are about to visit is maintained by a third party who is solely responsible for its content. We encourage you to read the privacy policy of every website you visit.

CANCEL CONTINUE
VASCULAR BIOGENICS
Copyright © 2021 Vascular Biogenics All rights reserved
  • TERMS AND CONDITIONS
  • PRIVACY
  • CONTACT US
Design by: Berliner Design  |  Site by: foothold-systems
Print Friendly, PDF & Email
Israel